<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022450</url>
  </required_header>
  <id_info>
    <org_study_id>200911033R</org_study_id>
    <nct_id>NCT01022450</nct_id>
  </id_info>
  <brief_title>Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients</brief_title>
  <official_title>Rhabdomyolysis - A Retrospective Study in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Analyze the various causes of breakdown of muscle fibers in hospitalized patients.

        2. Analyze the characteristics of these patients in Taiwan (including the drugs history,
           risk factors and the incidence of complications).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Find the causes of breakdown of muscle fibers in hospitalized patients through medical
           record review.

             -  especially drug-related

        2. Find the risk factors of muscle fibers breakdown.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Rhabdomyolysis</condition>
  <condition>Myopathy</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Neuroleptic Malignant Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who admitted to The National Taiwan University Hospital during 2003/1/1~2008/12/31
        with rhabdomyolysis or related muscle diseases dignosis and clinical presentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who admitted to The National Taiwan University Hospital during
             2003/1/1~2008/12/31 with the following discharge diagnosis: myoglobinuria,
             rhabdomyolysis, myopathy, toxic myopathy, malignant hyperthermia, neuroleptic
             malignant syndrome, polymyositis, myalgia and had acute neuromuscular illness
             presentations and serum creatinine kinase (CK) more than 5 times the upper limit of
             normal (male &gt; 900 IU/L; female &gt; 835 IU/L).

        Exclusion Criteria:

          -  Patients with recent myocardial infarction or stroke, unless clinical history,
             examination, or electromyography showed a concomitant myopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fe-Lin L Wu, MSCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Graduate Institute of Clinical Pharmacy, National Taiwan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fe-Lin L Wu, MSCP, PhD</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>88389</phone_ext>
    <email>flwu@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kwan-Dun Wu, MD, PhD</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>65014</phone_ext>
    <email>kdwu@ntuh.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10051</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan-Dun Wu, MD, PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65014</phone_ext>
      <email>kdwu@ntuh.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Fe-Lin L Wu, MSCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwan-Dun Wu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fe-Lin Lin Wu / Associate Professor, Director</name_title>
    <organization>Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University</organization>
  </responsible_party>
  <keyword>rhabdomyolysis</keyword>
  <keyword>myopathy</keyword>
  <keyword>acute renal failure</keyword>
  <keyword>neuroleptic malignant syndrome</keyword>
  <keyword>Pharmaceutical Preparations</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>fibrates</keyword>
  <keyword>creatine kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Rhabdomyolysis</mesh_term>
    <mesh_term>Neuroleptic Malignant Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

